characteristics.text: ERC000011
characteristics.characteristic: ENA-CHECKLIST
characteristics.text: 2022-02-28T16:29:54Z
characteristics.characteristic: ENA-FIRST-PUBLIC
characteristics.text: 2022-02-28T16:29:54Z
characteristics.characteristic: ENA-LAST-UPDATE
characteristics.text: SAMEA12289881
characteristics.characteristic: External Id
characteristics.text: Intensive Care Unit, Gunma University Hospital
characteristics.characteristic: INSDC center name
characteristics.text: 2022-02-28T16:29:54Z
characteristics.characteristic: INSDC first public
characteristics.text: 2022-02-28T16:29:54Z
characteristics.characteristic: INSDC last update
characteristics.text: public
characteristics.characteristic: INSDC status
characteristics.text: ERS9886723
characteristics.characteristic: SRA accession
characteristics.text: E-MTAB-11320:HeLa_1
characteristics.characteristic: Submitter Id
characteristics.text: ArrayExpress
characteristics.ontologyTerms: http://www.ebi.ac.uk/efo/EFO_0009737
characteristics.characteristic: broker name
characteristics.text: HeLa
characteristics.ontologyTerms: http://www.ebi.ac.uk/efo/EFO_0001185
characteristics.characteristic: cell line
characteristics.text: human
characteristics.ontologyTerms: http://purl.obolibrary.org/obo/NCBITaxon_9606
characteristics.characteristic: common name
characteristics.text: Protocols: Cancer cell lines were cultured in 6 cm dish at the concentration of 1×105 cells per dish. After two days, cells were treated with the indicated concentration of lidocaine and cultured for 24 h. Cells were harvested and applied for RNA preparation. Total RNAs from cultured cells were extracted using a FastGene RNA Premium kit (Nippon Genetics Inc., Tokyo, Japan) according to the manufacturer’s protocol. RNA quality was evaluated by RNA integrity number (RIN) using Agilent RNA6000 Pico Kit and the Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). High quality RNA samples (RIN>7.0) were applied for RNA-seq analysis. One microgram of total RNA was applied for preparing sequence libraries using KAPA mRNA HyperPrep Kit (Kapa Biosystems Inc, Wilmington, MA, USA) following the manufacturer’s instructions.
characteristics.characteristic: description
characteristics.text: adult
characteristics.characteristic: developmental stage
characteristics.text: cervical cancer
characteristics.ontologyTerms: http://www.ebi.ac.uk/efo/EFO_0001061
characteristics.characteristic: disease
characteristics.text: Homo sapiens
characteristics.characteristic: organism
characteristics.text: Homo sapiens
characteristics.ontologyTerms: http://purl.obolibrary.org/obo/NCBITaxon_9606
characteristics.characteristic: organism
characteristics.text: uterine cervix
characteristics.ontologyTerms: http://purl.obolibrary.org/obo/UBERON_0000002
characteristics.characteristic: organism part
characteristics.text: Homo sapiens
characteristics.characteristic: scientific_name
characteristics.text: HeLa_1
characteristics.characteristic: title